Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHLNASDAQ:ANLNASDAQ:HCAQNASDAQ:IVCP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHLAchilles Therapeutics$1.48$1.48$0.63▼$1.51$60.83M1.25658,738 shsN/AANLAdlai Nortye$1.47-2.0%$1.82$1.10▼$4.10$54.24M-0.8312,253 shs16,707 shsHCAQHealthCor Catalio Acquisition$0.70-0.2%$8.72$9.48▼$11.00$14.90MN/A114,974 shs218,548 shsIVCPSwiftmerge Acquisition$7.36-8.1%$10.43$8.80▼$13.39$50.34M0.0316,429 shs5,543 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHLAchilles Therapeutics0.00%0.00%0.00%0.00%+65.37%ANLAdlai Nortye0.00%-8.13%-22.22%-36.67%-56.38%HCAQHealthCor Catalio Acquisition-0.16%-16.15%+11.78%-18.92%-15.76%IVCPSwiftmerge Acquisition0.00%-16.74%-26.40%-3.54%-32.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHLAchilles TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AANLAdlai Nortye1.3677 of 5 stars3.33.00.00.00.00.00.0HCAQHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AIVCPSwiftmerge AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHLAchilles Therapeutics 0.00N/AN/AN/AANLAdlai Nortye 2.00Hold$9.00512.24% UpsideHCAQHealthCor Catalio Acquisition 0.00N/AN/AN/AIVCPSwiftmerge Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HCAQ, ACHL, IVCP, and ANL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025ANLAdlai NortyeHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHLAchilles TherapeuticsN/AN/AN/AN/A$3.49 per shareN/AANLAdlai Nortye$5M10.85N/AN/A$0.69 per share2.13HCAQHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AN/AIVCPSwiftmerge AcquisitionN/AN/A$0.43 per share17.28($0.52) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHLAchilles Therapeutics-$69.67M-$1.65N/AN/AN/AN/A-54.45%-47.68%8/12/2025 (Estimated)ANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)HCAQHealthCor Catalio AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AIVCPSwiftmerge Acquisition$3.42M-$0.02N/A∞N/AN/A-11.71%-0.23%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHLAchilles TherapeuticsN/AN/AN/AN/AN/AANLAdlai NortyeN/AN/AN/AN/AN/AHCAQHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AIVCPSwiftmerge AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHLAchilles TherapeuticsN/A6.046.04ANLAdlai Nortye0.021.411.41HCAQHealthCor Catalio AcquisitionN/A0.480.48IVCPSwiftmerge AcquisitionN/A0.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHLAchilles Therapeutics56.38%ANLAdlai Nortye35.21%HCAQHealthCor Catalio Acquisition84.18%IVCPSwiftmerge Acquisition38.10%Insider OwnershipCompanyInsider OwnershipACHLAchilles Therapeutics5.38%ANLAdlai NortyeN/AHCAQHealthCor Catalio AcquisitionN/AIVCPSwiftmerge Acquisition42.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHLAchilles Therapeutics25041.10 million38.89 millionNot OptionableANLAdlai Nortye12736.90 millionN/ANot OptionableHCAQHealthCor Catalio Acquisition221.31 millionN/ANot OptionableIVCPSwiftmerge Acquisition2,0216.84 million3.91 millionNot OptionableHCAQ, ACHL, IVCP, and ANL HeadlinesRecent News About These CompaniesSwiftmerge Acquisition (NASDAQ:IVCP) Shares Down 8.1% - Here's WhyJune 19 at 2:12 AM | marketbeat.comSwiftmerge Acquisition (NASDAQ:IVCP) Stock Price Down 3.2% - Should You Sell?May 29, 2025 | marketbeat.comBRS Resources Announces Update on AleAnna Energy, LLCDecember 16, 2024 | newsfilecorp.comAleAnna, Inc. Announces Completion of Business Combination between Swiftmerge Acquisition Corp. and AleAnna Energy, LLCDecember 13, 2024 | markets.businessinsider.comHow the (IVCP) price action is used to our AdvantageDecember 11, 2024 | news.stocktradersdaily.comTrend Tracker for (IVCP)November 21, 2024 | news.stocktradersdaily.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Swiftmerge Acquisition Corp. - IVCPOctober 14, 2024 | prnewswire.com(IVCP) Long Term Investment AnalysisSeptember 27, 2024 | news.stocktradersdaily.com(IVCP) Investment AnalysisSeptember 17, 2024 | news.stocktradersdaily.comSwiftmerge Acquisition Corp Ordinary Shares - Class AJanuary 5, 2024 | morningstar.comFarallon Capital: A Global and Diversified Hedge Fund and its Top Stock PicksNovember 13, 2023 | finance.yahoo.comMedia Sentiment Over TimeHCAQ, ACHL, IVCP, and ANL Company DescriptionsAchilles Therapeutics NASDAQ:ACHL$1.48 0.00 (0.00%) As of 03/26/2025Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Adlai Nortye NASDAQ:ANL$1.47 -0.03 (-2.00%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$1.46 0.00 (-0.34%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.HealthCor Catalio Acquisition NASDAQ:HCAQHealthCor Catalio Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.Swiftmerge Acquisition NASDAQ:IVCP$7.36 -0.65 (-8.11%) As of 06/17/2025Swiftmerge Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in West Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
